M
Monica Red Brewer
Researcher at Vanderbilt University
Publications - 18
Citations - 2457
Monica Red Brewer is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Cancer & Neratinib. The author has an hindex of 11, co-authored 17 publications receiving 1996 citations. Previous affiliations of Monica Red Brewer include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren Cross,Susan Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth D Hughes,Amar Rahi,Vivien Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham Richmond,Mireille Cantarini,Dong Wan Kim,Malcolm R Ranson,William Pao +25 more
TL;DR: A novel structurally distinct third-generation EGFR TKI that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR is reported.
Journal ArticleDOI
The juxtamembrane region of the EGF receptor functions as an activation domain.
Monica Red Brewer,Sung Hee Choi,Diego Alvarado,Katarina Moravcevic,Ambra Pozzi,Mark A. Lemmon,Graham Carpenter +6 more
TL;DR: How an uncharacterized lung cancer mutation in this JM activation domain (V665M) constitutively activates EGFR by augmenting its capacity to act as an acceptor in the asymmetric dimer is described.
Journal ArticleDOI
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
TL;DR: A previously unrecognized mode of mutant-specific intermolecular regulation for ErbB receptors is defined, demonstrating that activated EGFR mutants found in lung cancer preferentially assume the acceptor role when coexpressed with WT EGFR.
Journal ArticleDOI
EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib
Jean-Nicolas Gallant,Jonathan H. Sheehan,Timothy M. Shaver,Mark Bailey,Doron Lipson,Raghu Chandramohan,Monica Red Brewer,Sally York,Mark G. Kris,Jennifer A. Pietenpol,Marc Ladanyi,Vincent A. Miller,Siraj M. Ali,Jens Meiler,Christine M. Lovly +14 more
TL;DR: Oncogenic and drug-sensitive EGFR-KDD that is recurrent in lung, brain, and soft-tissue cancers is identified and it is documented that a patient with metastatic lung adenocarcinoma harboring the EGfr-K DD derived significant antitumor response from treatment with the EGFR inhibitor afatinib.
Journal ArticleDOI
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Ariella B. Hanker,Monica Red Brewer,Jonathan H. Sheehan,James P. Koch,Gregory Sliwoski,Rebecca J. Nagy,Richard B. Lanman,Michael F. Berger,David M. Hyman,David B. Solit,Jie He,Vincent A. Miller,Richard E. Cutler,Alshad S. Lalani,Darren Cross,Christine M. Lovly,Jens Meiler,Carlos L. Arteaga +17 more
TL;DR: It is speculated that HER2T798I may arise as a secondary mutation following response to effective HER2 tyrosine kinase inhibitors (TKI) in other cancers with HER2-activating mutations and this resistance may be overcome by other irreversible HER2 TKIs, such as afatinib.